SCHEMBL3920141

SCHEMBL3920141

Clc1ccc2c(Cl)[c]sc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCKDK O14874 1/20 0.39
MCL1 Q07820 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
ALDH1A1 P00352 5/20 0.35
CYP2A6 P11509 3/20 0.35
KDM4E B2RXH2 3/20 0.35
MEN1 O00255 3/20 0.35
MAPT P10636 3/20 0.35
KMT2A Q03164 3/20 0.35
GAA P10253 2/20 0.35
GFER P55789 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 3/20 0.34
TSHR P16473 2/20 0.34
CYP3A4 P08684 2/20 0.34
TDP1 Q9NUW8 1/20 0.34
TP53 P04637 1/20 0.33
AHR P35869 1/20 0.32
DAO P14920 1/20 0.32
ALOX12 P18054 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28503980 0.83 MIF (0.39) ALDH1A1KDM4EMAPTGAAHSD17B10
SCHEMBL147923 0.81 BCKDK (0.41) BCKDKALDH1A1MAPTGFERRAB9A
SCHEMBL3920159 0.81 BCL2L1 (0.41) MCL1ALDH1A1CYP2A6KDM4EMAPT
SCHEMBL694832 0.78 CYP2A6 (0.41) BCKDKMCL1RXFP1ALDH1A1CYP2A6
SCHEMBL21798536 0.77 TSHR (0.45) RXFP1ALDH1A1KDM4EMEN1MAPT
SCHEMBL11635073 0.74 HSD17B10 (0.46) ALDH1A1MAPTKMT2AHSD17B10TSHR
SCHEMBL693157 0.74 BCKDK (0.34) BCKDKMCL1RXFP1ALDH1A1CYP2A6
SCHEMBL4922527 0.70 BCKDK (0.53) BCKDKMCL1RXFP1ALDH1A1CYP2A6
SCHEMBL31228783 0.70 BCKDK (0.53) BCKDKMCL1RXFP1ALDH1A1CYP2A6
SCHEMBL884398 0.68 MPI (0.38) BCKDKALDH1A1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0125059-B1 HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES ICI AUSTRALIA LIMITED (AU) 1991-02-27 EP claimed
US-20090163538-A1 Tetrahydropyridothiophenes For Use In The Treatment Of Cancer PEKARI KLAUS 2009-06-25 US disclosed
US-7517986-B2 Tetrahydropyridothiophenes for use in the treatment of cancer 4SC AG (DE) 2009-04-14 US disclosed
EP-1756118-B1 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2008-05-28 EP disclosed
US-20070213360-A1 Tetrahydropyridothiophenes for Use in the Treatment of Cancer NYCOMED GMBH (DE) 2007-09-13 US disclosed
EP-1756118-A1 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Altana Pharma AG (DE) 2007-02-28 EP disclosed
WO-2005118592-A1 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER ALTANA PHARMA AG (DE) 2005-12-15 WO disclosed
EP-0125059-B1 HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES ICI AUSTRALIA LIMITED (AU) 1991-02-27 EP disclosed
US-4734121-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1988-03-29 US disclosed
US-4668275-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1987-05-26 US disclosed
EP-0107156-A1 Cyclohexane-1,3-dione derivatives, process for their preparation and their use in the control of undesirable plant growth BASF Aktiengesellschaft (DE) 1984-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163538-A1 Tetrahydropyridothiophenes For Use In The Treatment Of Cancer BCL2, BAX, MCL1 BCKDK 3208/4885MCL1 3/4885RXFP1 4020/4885
US-20070213360-A1 Tetrahydropyridothiophenes for Use in the Treatment of Cancer BCL2, BAX, MCL1 BCKDK 3178/4885MCL1 3/4885RXFP1 4099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.